Eli Lilly (LLY) news

Older LLY news events, each with the realized, point-in-time move the market made — page 6 of 8. Back to the LLY overview → · Full LLY reaction history →

Latest news

Recent LLY events, each with its measured reaction. (Page 6 of 8.)

DateHeadlineEventSource5-minTo close
Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast CancerPress releasePR Newswire+0.38%+0.56%
Children's Museum of Pittsburgh Receives $2.49 Million Grant from Lilly Endowment Inc.Press releasePR Web-0.09%-0.40%
CORE Kidney, Boehringer Ingelheim and Lilly Are Turning Up the Volume on Kidney Health at the 2025 Tournament of Roses® ParadePress releasePR Newswire-0.03%-1.40%
Lilly announces new $15 billion share repurchase program and seventh consecutive 15% dividend increasePress releasePR Newswire+0.04%-1.35%
Phase 3 results for Lilly's Jaypirca® (pirtobrutinib) in covalent BTK inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ASH Annual MeetingPress releasePR Newswire+0.04%-1.35%
Lilly announces $3 billion expansion of its recently acquired manufacturing facility in WisconsinPress releasePR Newswire+0.17%+0.28%
LILLY'S TIRZEPATIDE SUPERIOR TO WEGOVY® (SEMAGLUTIDE) IN HEAD-TO-HEAD TRIAL SHOWING AN AVERAGE WEIGHT LOSS OF 20.2% VS. 13.7%Press releaseCanada Newswire-0.82%-0.26%
Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%Press releasePR Newswire+0.09%+0.67%
Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALSPress releaseGlobeNewswire+0.80%+2.38%
Form 8-K ELI LILLY & Co For: Nov 19SEC filing · Form 8-KSEC EDGAR+0.80%+2.38%
Lilly announces changes on board of directorsPress releasePR Newswire+0.80%+2.38%
Lilly Canada remains steadfast in commitment to access options for patients amidst controversial CDA-AMC recommendation for Ebglyss™ (lebrikizumab)Press releaseCanada Newswire+0.01%+0.59%
Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dosePress releasePR Newswire+0.11%+1.25%
Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesityPress releasePR Newswire-0.39%-0.42%
Asha Therapeutics Awarded Barnett Drug Development Grant by the ALS Association to Advance Novel Intra-Molecular Glue Inhibitor of SARM1 to Clinic and Announces Appointment of Disarm Therapeutics’ Founders to Company’s Scientific Advisory BoardPress releaseBusiness Wire+0.52%-0.88%
Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeksPress releasePR Newswire+0.10%-2.30%
Lilly announces details of presentations at the 2024 American Society of Hematology (ASH) Annual MeetingPress releasePR Newswire+0.43%+0.38%
Lilly to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer SymposiumPress releasePR Newswire+0.79%-0.11%
Form 10-Q ELI LILLY & Co For: Sep 30SEC filing · Form 10-QSEC EDGAR+0.06%-0.04%
Form 8-K ELI LILLY & Co For: Oct 30SEC filing · Form 8-KSEC EDGAR-2.86%+6.12%
Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New ProductsPress releasePR Newswire-2.86%+6.12%
Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer's Disease Patients in Phase 3b studyPress releasePR Newswire+0.03%+0.09%
Lilly declares fourth-quarter 2024 dividendPress releasePR Newswire+0.04%+0.24%
Lilly's mirikizumab is first and only IL23p19 antagonist to report long-term, multi-year, sustained efficacy and safety data for both ulcerative colitis and Crohn's diseasePress releasePR Newswire-0.04%+0.08%
Lilly's EBGLYSS™ (lebrikizumab-lbkz) demonstrated meaningful improvement in skin clearance and itch relief in the majority of patients with moderate-to-severe atopic dermatitis who discontinued dupilumabPress releasePR Newswire-0.20%-0.78%
HiveMQ Honors IoT Excellence with Inaugural MQTT Innovation AwardsPress releasePR Web-0.43%-0.78%
Lilly's Kisunla™ (donanemab-azbt) Receives Marketing Authorization in Great Britain for the Treatment of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in Adult Patients Who Are Apolipoprotein E ?4 Heterozygotes or Non-CarriersPress releasePR Newswire+0.09%-0.26%
Lilly confirms date and conference call for third-quarter 2024 financial results announcementPress releasePR Newswire+0.26%+1.24%
Survey reveals 8 in 10 Americans with ulcerative colitis struggle to find a public restroom during emergenciesPress releasePR Newswire-0.45%+0.70%
Lilly reports one-year histologic outcomes in Phase 3 study of mirikizumab compared to ustekinumab for Crohn's diseasePress releasePR Newswire-0.69%-0.69%
Lilly announces new $4.5 billion site - the Lilly Medicine Foundry - to drive innovation in drug production and make medicines for clinical trialsPress releasePR Newswire+0.15%+1.26%
STEM Exploration Day Ignite Girls Passion for Careers in STEMPress releasePR Web+1.75%+2.83%
New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitisPress releasePR Newswire+0.45%-0.77%
Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's DiseasePress releasePR Newswire-0.09%+0.25%
FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic DermatitisPress releasePR Newswire-0.79%-0.62%
Lilly expands manufacturing footprint in Ireland with $1.8 billion investmentPress releasePR Newswire-0.30%+1.16%
Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetesPress releasePR Newswire-0.17%-0.38%
With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetesPress releasePR Newswire-0.16%+0.21%
Form 8-K ELI LILLY & Co For: Sep 05SEC filing · Form 8-KSEC EDGAR-0.06%-0.54%
Lilly appoints Lucas Montarce as executive vice president and chief financial officerPress releasePR Newswire-0.06%-0.54%
In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulinPress releasePR Newswire-0.43%-3.02%
Lilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countriesPress releasePR Newswire-0.68%-0.48%
Lilly Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for OMVOH® (mirikizumab) for adults with moderately to severely active ulcerative colitis (UC)Press releaseCanada Newswire-0.09%-0.13%
Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesityPress releasePR Newswire+0.51%+0.21%
Lilly to participate in Morgan Stanley 22nd Annual Global Healthcare ConferencePress releasePR Newswire+0.70%-1.15%
Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweightPress releasePR Newswire+1.61%+1.93%
Form 8-K ELI LILLY & Co For: Aug 13SEC filing · Form 8-KSEC EDGAR-0.34%-0.03%
Lilly announces retirement of Marschall S. Runge from its Board of DirectorsPress releasePR Newswire-0.34%-0.03%
Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel DiseasePress releasePR Newswire-0.31%-0.68%
Form 8-K/A LL Flooring Holdings, For: Aug 07SEC filing · Form 8-KSEC EDGAR-0.31%-0.68%

Each headline opens its own page with the full realized reaction — the move the market actually made, measured from the news timestamp.

Stop guessing what the event means.

claude mcp add news-quantified
Get free API keyTry the playground